查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1621586

疫苗契约製造市场：按类型、功能和应用分类 - 2025-2030 年全球预测

Vaccine Contract Manufacturing Market by Type (Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine), Function (Downstream, Upstream), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年疫苗契约製造市场的市场规模为50.6亿美元，预计2024年将达到55.1亿美元，复合年增长率为9.21%，预计到2030年将达到93.9亿美元。

疫苗契约製造市场主要涉及将疫苗生产流程外包给具有大规模生产、合规性和先进技术平台支援专业能力的第三方製造商。随着全球健康挑战的加剧，包括新兴感染疾病的出现和快速部署疫苗的需要，这个领域变得越来越重要。对疫苗契约製造的需求源于对疫苗不断增长的需求，特别是在大流行期间，速度和产能是关键瓶颈。应用涵盖多种治疗领域，包括感染疾病预防性疫苗、肿瘤学以及 mRNA 技术等创新方法。该领域的最终用户主要是製药公司、医疗保健提供者和政府机构。

主要市场统计
基准年[2023] 50.6亿美元
预测年份 [2024] 55.1亿美元
预测年份 [2030] 93.9亿美元
复合年增长率（%） 9.21%

市场成长受到多种因素的推动，例如药品供应链的全球化、疫苗製造方法的技术进步以及医疗保健支出的增加。此外，人们对疾病预防意识的增强以及对流行病和大流行病防备的重视也推动了需求。机会存在于正在大力投资医疗基础设施和核酸疫苗等新型疫苗技术的新兴市场。积极与生物技术公司合作并增加对灵活製造技术的投资可以提供竞争优势。然而，严格的法规环境、高昂的初始资本投资以及疫苗生产中基因改造生物的道德担忧等挑战可能会阻碍成长。

对自动化和生物工艺创新的投资是潜在成长的领域。此外，还应优先研究改善低温运输物流以及提高疫苗功效和安全性。该市场的特点是技术快速进步以及公司之间旨在发挥集体优势的联盟。为了抓住潜在机会，企业应专注于策略联盟、横向扩张以实现能力多元化，并集中投资研发以推动创新。因此，了解监管环境并开发适合每个市场的业务对于在这个动态环境中实现永续成长和获得竞争优势至关重要。

市场动态：揭示快速发展的疫苗契约製造市场的关键市场洞察

疫苗契约製造市场正在因供需的动态相互作用而发生转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 疫苗需求增加导致契约製造产能增加
    • 委託製造带来的成本和时间节省的主要优势
    • 全球疫苗接种覆盖率
  • 市场限制因素
    • 对成熟疫苗製造商外包的限制
  • 市场机会
    • 全球需求不断增长，以满足不断增长的各年龄层人口的需求
    • 创新和强大的疫苗研发管线
    • 政府对加快疫苗生产的有利见解和指导方针
  • 市场挑战
    • 製药公司正在将製造业务纳入内部，以获得策略控制权。

波特五力：驾驭疫苗契约製造市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解疫苗契约製造市场的外部影响

外部宏观环境因素在塑造疫苗契约製造市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解疫苗契约製造市场的竞争状况

疫苗契约製造市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵疫苗契约製造市场供应商绩效评估

FPNV定位矩阵是评估疫苗契约製造市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製疫苗契约製造市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对疫苗契约製造市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 疫苗需求增加扩大了契约製造的产能
      • 合约服务的主要好处包括节省成本和时间
      • 世界各地的疫苗接种率
    • 抑制因素
      • 老牌疫苗製造商的外包有限
    • 机会
      • 全球需求不断增长，以满足不断增长的不同年龄层人口的需求
      • 创新和强大的疫苗产品线
      • 政府对加速疫苗生产的有利观点和指导方针
    • 任务
      • 製药公司在内部进行生产业务以获得策略控制
  • 市场区隔分析
    • 类型：更多采用减毒疫苗来增强免疫力
    • 特点：增加下游加工配方的使用，包括生物产品精製和配方
    • 应用：契约製造人用疫苗以保护人们免受感染疾病的潜力不断增长
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 疫苗契约製造市场：依类型

  • 减毒疫苗
  • DNA疫苗
  • 灭活疫苗
  • 次单位疫苗
  • 类毒素疫苗

第七章 疫苗契约製造市场：依功能分类

  • 下游
    • 分析和品管研究
    • 填充和整理操作
    • 包裹
  • 上游
    • 细菌表现系统
    • 桿状病毒或昆虫表现系统
    • 哺乳动物表达系统
    • 酵母表现系统

第八章疫苗契约製造市场：依应用分类

  • 人类使用
  • 兽医

第九章 北美和南美疫苗契约製造市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太疫苗契约製造市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲疫苗契约製造市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Vaxcyte 和 Lonza 扩大频谱肺炎链球菌结合疫苗 (PCV) 的全球商业生产合作
    • 牛津大学以 1500 万欧元从梅里埃研究所收购 ABL Europe
    • 辉瑞与三星生物製品公司签署价值 1.83 亿美元的契约製造协议
  • 战略分析和建议

公司名单

  • AbbVie Inc
  • Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc.
  • Aton（Shanghai）Biotech Co., Ltd.
  • Avid Bioservices, Inc.
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CSL Limited
  • Curia Global, Inc.
  • Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • Emergent BioSolutions Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc. by FUJIFILM Corporation
  • Gedeon Richter PLC
  • GlaxoSmithKline PLC
  • ICON PLC
  • IDT Biologika GmbH
  • KBI Biopharma, Inc. by JSR Corporation
  • Klocke Pharma-Service GmbH
  • Lonza Group Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Pfizer Inc.
  • Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Serum Institute of India
  • Vetter Pharma-Fertigung GmbH & Co. KG
Product Code: MRR-430D42AA0DC4

The Vaccine Contract Manufacturing Market was valued at USD 5.06 billion in 2023, expected to reach USD 5.51 billion in 2024, and is projected to grow at a CAGR of 9.21%, to USD 9.39 billion by 2030.

The Vaccine Contract Manufacturing market primarily involves the outsourcing of vaccine production processes to third-party manufacturers who hold specialized capabilities in handling large-scale production, regulatory compliance, and advanced technology platforms. This sector is increasingly crucial due to escalating global health challenges, which include the emergence of new infectious diseases and the need for rapid vaccine deployment. The necessity of vaccine contract manufacturing arises from the growing demand for vaccines, especially during pandemics, where speed and capacity become critical bottlenecks. Applications span across various therapeutic areas including preventative vaccines for infectious diseases, oncology, and through innovative modalities like mRNA technology. End-users in this realm primarily include pharmaceutical companies, healthcare providers, and government agencies.

KEY MARKET STATISTICS
Base Year [2023] USD 5.06 billion
Estimated Year [2024] USD 5.51 billion
Forecast Year [2030] USD 9.39 billion
CAGR (%) 9.21%

Market growth is propelled by several factors, including the globalization of pharmaceutical supply chains, technological advancements in vaccine production methods, and increasing healthcare expenditure. Moreover, the rise in awareness regarding disease prevention and the emphasis on endemic and pandemic preparedness also fuel demand. Opportunities lie in emerging markets that are investing heavily in healthcare infrastructure and in novel vaccine technologies such as nucleic acid vaccines. Venturing into partnerships with biotech firms and increasing investments in flexible manufacturing technology could provide competitive advantages. However, challenges such as stringent regulatory environments, high initial capital investments, and ethical concerns over genetically modified organisms in vaccine production can impede growth.

Investment in automation and bioprocessing innovations represents potential areas for growth. Additionally, research into improving cold chain logistics and enhancing vaccine efficacy and safety profiles should be prioritized. The market is typified by rapid technological advancements and partnerships between entities aiming to leverage collective strengths. To seize potential opportunities, firms should focus on strategic alliances, horizontal expansion to diversify capabilities, and heavy investment in R&D to propel innovation. Hence, understanding regulatory landscapes and tailoring operations for each market are vital for sustained growth and competitive advantage in this dynamic landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccine Contract Manufacturing Market

The Vaccine Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for vaccines leading to capacity expansion by contract manufacturers
    • Key advantages such as cost and time saving offered by contract services
    • Vaccination coverage across the globe
  • Market Restraints
    • Limited outsourcing by well-established vaccine manufacturers
  • Market Opportunities
    • Rising global demand to cater to the growing population of varied age groups
    • Innovation and robust vaccine pipeline
    • Favorable government insights and guidelines to speed up the vaccine manufacturing
  • Market Challenges
    • Pharma companies manufacturing operations in-house to gain strategic control

Porter's Five Forces: A Strategic Tool for Navigating the Vaccine Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccine Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccine Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccine Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccine Contract Manufacturing Market

A detailed market share analysis in the Vaccine Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccine Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccine Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccine Contract Manufacturing Market

A strategic analysis of the Vaccine Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine, Subunit Vaccines, and Toxoid Vaccines.
  • Based on Function, market is studied across Downstream and Upstream. The Downstream is further studied across Analytical & QC studies, Fill & Finish Operations, and Packaging. The Upstream is further studied across Bacterial Expression Systems, Baculovirus or Insect Expression Systems, Mammalian Expression Systems, and Yeast Expression Systems.
  • Based on Application, market is studied across Human Use and Veterinary.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for vaccines leading to capacity expansion by contract manufacturers
      • 5.1.1.2. Key advantages such as cost and time saving offered by contract services
      • 5.1.1.3. Vaccination coverage across the globe
    • 5.1.2. Restraints
      • 5.1.2.1. Limited outsourcing by well-established vaccine manufacturers
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising global demand to cater to the growing population of varied age groups
      • 5.1.3.2. Innovation and robust vaccine pipeline
      • 5.1.3.3. Favorable government insights and guidelines to speed up the vaccine manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Pharma companies manufacturing operations in-house to gain strategic control
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of attenuated vaccines to enhance immune systems
    • 5.2.2. Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts
    • 5.2.3. Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccine Contract Manufacturing Market, by Type

  • 6.1. Introduction
  • 6.2. Attenuated Vaccine
  • 6.3. DNA Vaccines
  • 6.4. Inactivated Vaccine
  • 6.5. Subunit Vaccines
  • 6.6. Toxoid Vaccines

7. Vaccine Contract Manufacturing Market, by Function

  • 7.1. Introduction
  • 7.2. Downstream
    • 7.2.1. Analytical & QC studies
    • 7.2.2. Fill & Finish Operations
    • 7.2.3. Packaging
  • 7.3. Upstream
    • 7.3.1. Bacterial Expression Systems
    • 7.3.2. Baculovirus or Insect Expression Systems
    • 7.3.3. Mammalian Expression Systems
    • 7.3.4. Yeast Expression Systems

8. Vaccine Contract Manufacturing Market, by Application

  • 8.1. Introduction
  • 8.2. Human Use
  • 8.3. Veterinary

9. Americas Vaccine Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Vaccine Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Vaccine Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
    • 12.3.2. Oxford Acquires ABL Europe From Institut Merieux For EUR 15 Mn
    • 12.3.3. Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc
  • 2. Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc.
  • 3. Aton (Shanghai) Biotech Co., Ltd.
  • 4. Avid Bioservices, Inc.
  • 5. Catalent, Inc.
  • 6. Charles River Laboratories International, Inc.
  • 7. CSL Limited
  • 8. Curia Global, Inc.
  • 9. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • 10. Emergent BioSolutions Inc.
  • 11. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • 12. Gedeon Richter PLC
  • 13. GlaxoSmithKline PLC
  • 14. ICON PLC
  • 15. IDT Biologika GmbH
  • 16. KBI Biopharma, Inc. by JSR Corporation
  • 17. Klocke Pharma-Service GmbH
  • 18. Lonza Group Ltd.
  • 19. Merck KGaA
  • 20. Moderna, Inc.
  • 21. Pfizer Inc.
  • 22. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • 23. Recipharm AB
  • 24. Serum Institute of India
  • 25. Vetter Pharma-Fertigung GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. VACCINE CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINE CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACULOVIRUS OR INSECT EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VETERINARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023